Disclosure NewswireTMiCrowdNewswire - Sep 6, 2016
RENO, NV – Cancer.im, Inc., a Viratech Corp Company (OTC: VIRA) announced today that Dr. Michael Nelson will join its Medical Advisory Board.
“I am extremely excited to be involved in this cutting edge technology. By providing individuals with early and specific markers of cancer and other diseases we are able to offer more targeted therapeutic interventions with less toxic side effects. Cancer is soon to overtake heart disease as the leading cause of death in the world, so it’s imperative that we have tools that allow us to detect early changes before they become life threatening. Metabolic changes precede the cancer diagnosis in over 90% of the cases. The P Scan tests offer clinicians and patients an accurate and reproducible way to assay risk and treatment effectiveness. I am looking forward to seeing this technology become standardized throughout the world,” states Dr. Nelson.
“Dr. Nelson is a valuable addition to our team, especially with his experience and understanding of Functional Medicine and Health,” said Fred Schiemann, CEO of Viratech Corp. Mr. Schiemann continues, “In addition to his exceptional ability as a clinician, he also has many years of working with well-known experts in the field of health care and new medical research.”
Dr. Michael Nelson has a doctorate in Chiropractic Medicine from Western States University in Portland Oregon, and a Bachelor’s Degree in Respiratory Science. He is a practicing chiropractic physician with over 1500 hours of post graduate training in functional medicine. As a practitioner Dr. Nelson has a personal passion for reversing chronic conditions such as thyroid dysfunction, type II diabetes, autoimmunity, fibromyalgia, hormone imbalances, metabolic syndrome, and hypertension.
In addition to his years in private practice, Dr. Nelson has developed and marketed nutraceutical formulations for brain health, immunity, and adrenal fatigue. He is well respected for his clinical acumen and his empathetic concern for his patients.
About Cancer.im, Inc.
Cancer.im Inc. is a purpose-driven corporation with a mission “To Change The Way People View and Manage Cancer.” Cancer.im is a for-profit social network that supports a parallel and independently run non-profit. In addition, Cancer.im, Inc. is working on commercialization of new noninvasive diagnostic technology.
On October 27, 2007, Dr. Nikolaou, on behalf of Fox Chase Medical Center, published a double blind placebo controlled study titled “Quality of Life (QOL) Supersedes the Classic Predictors of Survival in Locally Advanced Non-Small Cell Lung Cancer (NSCLC).” This study concluded that by raising a cancer patient’s quality of life via the European Organization for Research and Treatment of Cancer (EORTC QLQ-C30 index), you could directly lower the incidence of morbidity in a cancer patient, regardless of treatment.
In 2008, Cancer.im CEO Chris Ryan with oncologist Dr. Mahesh Kanojia, Dr. Barkat Charania and Dr. Kevin Buckman adapted the above referenced study into a modular 15-part best practice navigation element and guide on teaching and assisting cancer patients in raising their quality of life.
In 2011 this adaption was published under the title “Method of Lowering a Cancer Patients’ Morbidity Rate by Increasing Quality of Life of Patient, by Leveraging Cause Based Electronic Support Networks”, and later renamed “The Robert Ryan Cancer Protocol” in honor of the cancer patient who inspired the study.
The Cancer.im Inc. vision is based on the Robert Ryan Cancer Protocol with a modular 15-part best practice guide on teaching and assisting cancer patients and their loved ones on the importance of Quality of Life and how to raise it when managing a diagnosis of cancer.
“Cancer.im is about empowering the cancer patients, caretakers and survivors of the network. It is an honor to serve this project, for it draws the best people who together through collaboration bring the best out of each other. The purpose of Cancer.im is to convert a cancer patient from hopeless to hopeful, while teaching their support network how to be helpful, while not being a hindrance,” says Chris Ryan CEO Cancer.im Inc.
In 2016, there will be an estimated 1,685,210 new cancer cases diagnosed and 595,690 cancer deaths in the US. Cancer accounts for 1 in every 4 deaths, second only to heart disease as the most common cause of death. The monetary cost seems irrelevant to the loss of life. Overall costs for cancer care by 2020 are estimated to be $158 billion not counting all the other associated costs of cancer.
About Viratech, Corp. and Cancer.im, Inc.
Viratech and its subsidiary are a software company focusing on developing disruptor based applications in the communication broadcasting, work flow management, crowd sourced labor and social media fields. Additionally, Viratech and its wholly owned subsidiary develop medical products for the early detection of cancer and other diseases.
Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. Forward-looking statements in this press release include statements regarding our belief about the market applications. The following important factors, among others, have affected and, in the future could affect, the our actual results: the effect of new branding and marketing initiatives, the integration of new leadership, the introduction and acceptance of new products, the levels and particular directions of research and product development by our customers, the impact of the growing number of producers of biotechnology research and diagnostics products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and results of our research and product development efforts and those of companies in which we have invested or with which we have formed strategic relationships. For additional information concerning such factors, see the section titled “Risk Factors” in our annual report and quarterly reports. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.
Contact: Mr. Fred Schiemann, CEO/Director
Chris Ryan www.linkedin.com/in/cancer/